PL2852671T3 - Wytwarzanie ludzkich komórek ips z użyciem syntetycznego samoreplikującego się rna - Google Patents

Wytwarzanie ludzkich komórek ips z użyciem syntetycznego samoreplikującego się rna

Info

Publication number
PL2852671T3
PL2852671T3 PL13794196T PL13794196T PL2852671T3 PL 2852671 T3 PL2852671 T3 PL 2852671T3 PL 13794196 T PL13794196 T PL 13794196T PL 13794196 T PL13794196 T PL 13794196T PL 2852671 T3 PL2852671 T3 PL 2852671T3
Authority
PL
Poland
Prior art keywords
selfplicating
rna
synthetic
manufacture
ips cells
Prior art date
Application number
PL13794196T
Other languages
English (en)
Inventor
Steven F. Dowdy
Naohisa YOSHIOKA
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of PL2852671T3 publication Critical patent/PL2852671T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/604—Klf-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/605—Nanog
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/606—Transcription factors c-Myc
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1307—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Transplantation (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Prostheses (AREA)
PL13794196T 2012-05-21 2013-05-21 Wytwarzanie ludzkich komórek ips z użyciem syntetycznego samoreplikującego się rna PL2852671T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261649876P 2012-05-21 2012-05-21
US201361798229P 2013-03-15 2013-03-15
EP13794196.9A EP2852671B1 (en) 2012-05-21 2013-05-21 Generation of human ips cells by a synthetic self- replicative rna
PCT/US2013/041980 WO2013177133A2 (en) 2012-05-21 2013-05-21 Generation of human ips cells by a synthetic self- replicative rna

Publications (1)

Publication Number Publication Date
PL2852671T3 true PL2852671T3 (pl) 2019-06-28

Family

ID=49624495

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13794196T PL2852671T3 (pl) 2012-05-21 2013-05-21 Wytwarzanie ludzkich komórek ips z użyciem syntetycznego samoreplikującego się rna

Country Status (14)

Country Link
US (4) US9862930B2 (pl)
EP (1) EP2852671B1 (pl)
JP (1) JP6396893B2 (pl)
CN (1) CN104508131B (pl)
AU (1) AU2013266496B2 (pl)
CA (2) CA3279208A1 (pl)
DK (1) DK2852671T3 (pl)
ES (1) ES2698527T3 (pl)
HU (1) HUE041853T2 (pl)
IL (2) IL235628B (pl)
PL (1) PL2852671T3 (pl)
PT (1) PT2852671T (pl)
SG (1) SG11201407595UA (pl)
WO (1) WO2013177133A2 (pl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3169310A1 (en) 2014-07-15 2017-05-24 Life Technologies Corporation Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
AU2016355191B2 (en) * 2015-11-18 2023-06-29 Orbis Health Solutions Llc T7 alpha viral vector system
MX391337B (es) 2016-04-13 2025-03-21 Janssen Pharmaceuticals Inc Star Sistemas de replicón de arterivirus recombinantes y usos de estos.
JP7146211B2 (ja) * 2017-02-24 2022-10-04 剛士 田邊 人工多能性幹細胞の作製方法
US20190352604A1 (en) * 2017-02-24 2019-11-21 Koji Tanabe Nerve cell production method
CA3068917A1 (en) 2017-07-05 2019-01-10 Wisconsin Alumni Research Foundation Mineral coated microparticles for co-delivery of anti-inflammatory molecules with nucleic acids to improve gene delivery outcomes
US12291717B2 (en) 2017-09-13 2025-05-06 Biontech Rna Pharmaceuticals Gmbh RNA replicon for reprogramming somatic cells
US11229699B2 (en) 2017-11-06 2022-01-25 Intervet Inc. Feline calicivirus vaccine
US20200392455A1 (en) * 2017-11-30 2020-12-17 I Peace, Inc. Nerve cell production method
KR102143320B1 (ko) * 2018-08-28 2020-08-12 주식회사 스템랩 합성 메신저 rna를 이용하여 소변세포를 신경줄기세포로 직접 역분화하는 방법
KR20210068485A (ko) 2018-09-28 2021-06-09 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 노화를 역전시키고 기관 및 조직 재생을 촉진시키기 위한 세포 재프로그래밍
US12274733B2 (en) 2018-09-28 2025-04-15 President And Fellows Of Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
CA3115480A1 (en) * 2018-10-08 2020-04-16 Janssen Pharmaceuticals, Inc. Alphavirus-based replicons for administration of biotherapeutics
WO2020146690A1 (en) * 2019-01-10 2020-07-16 Massachusetts Institute Of Technology Methods for in vitro evolution of rna replicons
US20220186259A1 (en) * 2019-06-27 2022-06-16 Emd Millipore Corporation Cell expansion with self-replicating rna vectors expressing immortalization proteins
KR102249776B1 (ko) * 2019-11-25 2021-05-10 연세대학교 산학협력단 개선된 생체 내 리프로그래밍 시스템 및 이를 이용한 세포 전환 방법
CN116196405A (zh) 2019-12-31 2023-06-02 伊利克斯根治疗公司 核酸和蛋白质向细胞和组织的基于温度的瞬时递送
JP2023517992A (ja) 2020-03-12 2023-04-27 インスティチュート フォー ベーシック サイエンス ゲノム配列変異を有する細胞死滅誘導用組成物及び該組成物を用いた細胞死滅誘導方法
EP4209593A4 (en) * 2020-09-04 2024-10-09 Heartseed Inc. IPS CELL QUALITY IMPROVING AGENT, METHOD FOR PRODUCING IPS CELLS, IPS CELLS, AND COMPOSITION FOR PRODUCING IPS CELLS
CN112458064A (zh) * 2020-11-20 2021-03-09 广西大学 盖他病毒全长感染性克隆、复制子系统及其制备和应用
CN112852841A (zh) * 2021-02-03 2021-05-28 郑州大学 一种高效表达目的蛋白的顺式复制子rna构建体
AU2022241885A1 (en) 2021-03-25 2023-11-09 Bluerock Therapeutics Lp Methods for obtaining induced pluripotent stem cells
JP2024517848A (ja) * 2021-05-04 2024-04-23 モグリファイ リミテッド 細胞変換
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
US20230042860A1 (en) * 2021-07-15 2023-02-09 Turn Biotechnologies, Inc. Polycistronic expression vectors
WO2023288288A1 (en) * 2021-07-15 2023-01-19 Turn Biotechnologies, Inc. Synthetic, persistent rna constructs with on/off mechanism for controlled expression and methods of use
US20230044997A1 (en) * 2021-07-15 2023-02-09 Turn Biotechnologies, Inc. Synthetic, persistent rna constructs and methods of use for cell rejuvenation and for treatment
AU2022420484A1 (en) * 2021-12-20 2024-06-13 Elevatebio Technologies, Inc. Compositions and methods for cellular reprogramming using circular rna
EP4514947A1 (en) 2022-04-28 2025-03-05 Bluerock Therapeutics LP Novel sites for safe genomic integration and methods of use thereof
CN119998259A (zh) 2022-06-23 2025-05-13 特恩生物技术公司 脂质结构及包含其的组合物
TW202440914A (zh) 2022-12-13 2024-10-16 美商藍岩醫療公司 工程化之第v型rna可程式化核酸內切酶及其用途
US12252518B2 (en) 2023-01-06 2025-03-18 Life Biosciences, Inc. Methods of treating non-arteritic anterior ischemic optic neuropathy
WO2024167814A1 (en) 2023-02-06 2024-08-15 Bluerock Therapeutics Lp Degron fusion proteins and methods of production and use thereof
WO2025076291A1 (en) 2023-10-06 2025-04-10 Bluerock Therapeutics Lp Engineered type v rna programmable endonucleases and their uses
WO2025166063A1 (en) 2024-01-31 2025-08-07 Bluerock Therapeutics Lp Igfbp2 in cell culture
WO2025207481A1 (en) 2024-03-25 2025-10-02 Bluerock Therapeutics Lp Measuring viability in cell aggregates
WO2026006245A1 (en) 2024-06-25 2026-01-02 Bluerock Therapeutics Lp Three-dimensional culturing of pluripotent stem cells for improved differentiability

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
JPH06504997A (ja) 1990-12-06 1994-06-09 アフィメトリックス，　インコーポレイテッド 非常に大きい規模の固定化されたポリマーの合成
EP1997900A3 (en) * 1996-04-05 2010-10-06 Novartis Vaccines and Diagnostics, Inc. Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US5811407A (en) * 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US20030232324A1 (en) * 2001-05-31 2003-12-18 Chiron Corporation Chimeric alphavirus replicon particles
EP1432791B2 (en) 2001-09-06 2013-10-23 Alphavax, Inc. Alphavirus replicon vector systems
EP1386926A1 (en) 2002-07-29 2004-02-04 Bioxtal Methods for producing labelled recombinant polypeptides and uses thereof
US20050271639A1 (en) * 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
CA2509979C (en) 2002-12-13 2013-02-26 Alphavax, Inc. Alphavirus particles and methods for preparation
CN1791678A (zh) 2003-03-20 2006-06-21 阿尔法瓦克斯公司 改进的甲病毒复制子和辅助构建体
US20060198854A1 (en) 2004-12-28 2006-09-07 Peter Pushko Vector platforms derived from the alphavirus vaccines
US9005966B2 (en) * 2007-11-19 2015-04-14 The Regents Of The University Of California Generation of pluripotent cells from fibroblasts
EP2072618A1 (en) 2007-12-14 2009-06-24 Johannes Gutenberg-Universität Mainz Use of RNA for reprogramming somatic cells
GB0801215D0 (en) * 2008-01-23 2008-02-27 Univ Sheffield Cell re-programming
WO2009115295A1 (en) * 2008-03-17 2009-09-24 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Vectors and methods for generating vector-free induced pluripotent stem (ips) cells using site-specific recombination
ES2644588T3 (es) * 2008-06-13 2017-11-29 Whitehead Institute For Biomedical Research Programación y reprogramación de células
WO2010028019A2 (en) 2008-09-03 2010-03-11 The General Hospital Corporation Direct reprogramming of somatic cells using non-integrating vectors
CA2753845C (en) * 2009-02-27 2019-10-29 Kyoto University Nuclear reprogramming substance comprising glis1
US20120128714A1 (en) * 2009-04-08 2012-05-24 Wolchok Jedd D Alphavirus Replicon Particles Expressing TRP2
AU2010236632A1 (en) 2009-04-13 2011-09-15 The Regents Of The University Of California Methods and compositions for stem cell cultures
WO2011109612A2 (en) * 2010-03-03 2011-09-09 The General Hospital Corporation Method for selecting an ips cell
WO2011130624A2 (en) * 2010-04-16 2011-10-20 Immune Disease Institute, Inc. Sustained polypeptide expression from synthetic, modified rnas and uses thereof
AU2013343864B2 (en) 2012-11-09 2019-04-04 BioNTech SE Method for cellular RNA expression

Also Published As

Publication number Publication date
SG11201407595UA (en) 2014-12-30
US10370646B2 (en) 2019-08-06
ES2698527T3 (es) 2019-02-05
IL235628B (en) 2020-03-31
PT2852671T (pt) 2018-11-29
IL272917A (en) 2020-04-30
CN104508131A (zh) 2015-04-08
WO2013177133A2 (en) 2013-11-28
US20190338252A1 (en) 2019-11-07
JP2015519898A (ja) 2015-07-16
EP2852671A4 (en) 2015-12-23
US9862930B2 (en) 2018-01-09
US10793833B2 (en) 2020-10-06
CA2873964C (en) 2025-09-16
AU2013266496A1 (en) 2014-11-27
CA2873964A1 (en) 2013-11-28
AU2013266496B2 (en) 2018-08-09
CN104508131B (zh) 2018-11-23
EP2852671A2 (en) 2015-04-01
US20210108179A1 (en) 2021-04-15
HUE041853T2 (hu) 2019-05-28
EP2852671B1 (en) 2018-08-22
JP6396893B2 (ja) 2018-09-26
IL235628A0 (en) 2015-01-29
US20150159143A1 (en) 2015-06-11
DK2852671T3 (en) 2018-12-10
WO2013177133A3 (en) 2014-03-20
CA3279208A1 (en) 2025-10-30
US20180216079A1 (en) 2018-08-02

Similar Documents

Publication Publication Date Title
PL2852671T3 (pl) Wytwarzanie ludzkich komórek ips z użyciem syntetycznego samoreplikującego się rna
IL284998A (en) Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
IL237592B (en) Methods of expanding and assessing b cells and using expanded b cells to treat disease
DK2863990T3 (da) Medicinsk mikroelektrode
LT2885010T (lt) Tautopatijos gydymo būdai
DK2900806T3 (da) Tredimensionel celledyrkning
EP2892596A4 (en) Valsalva MASK
LT3091141T (lt) Lengvesnės grindų plokštės iš mažiau medžiagų
EP2935546A4 (en) BIORAFFINATION OF RAW TALL OIL
BR112014007029A2 (pt) métodos aperfeiçoados de terapia gênica
EP2832328A4 (en) DISPOSABLE UNDERWEAR
EP2832327A4 (en) DISPOSABLE UNDERWEAR
HRP20181599T1 (hr) Proizvodnja i upotreba bakterijskog histamina
BR112014015814A2 (pt) fralda descartável
EP2821053A4 (en) CLEANSING COMPOSITION FOR THE SKIN
EP2699467A4 (en) SEGMENTED RAIL AND RAIL SEGMENT THEREFOR
BR112014012223A2 (pt) fralda descartável
EP2889368A4 (en) PROTEIN PRODUCTION ACCELERATOR
BR112014026553A2 (pt) Fralda descartável
EP2810665A4 (en) bio-implant
HRP20182057T1 (hr) Temperaturno stabilni vodeni pripravci klokintocet-meksila
BR112014012225A2 (pt) fralda descartável
EP2849764A4 (en) TRACE ELEMENT SOLUTION
EP2924188C0 (en) CONSTRUCTION PANEL SET
EP2863894A4 (en) fenofibrate